CD3-CD16-CD56bright immunoregulatory NK cells are increased in the tumor microenvironment and inversely correlate with advanced stages in patients with papillary thyroid cancer

Thyroid

Volumn 23, Issue 12, 2013, Pages 1561-1568

  Gogali, Foteini ^a   Paterakis, George ^b   Rassidakis, George Z ^c   Liakou, Chrysoula I ^a   Liapi, Charis ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b G GENNIMATAS GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; CELL INFILTRATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; INNATE IMMUNITY; MALE; NATURAL KILLER CELL; NODULAR GOITER; PRIORITY JOURNAL; THYROID CARCINOMA; THYROIDECTOMY; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ADOLESCENT; ADULT; AGED; CARCINOMA, PAPILLARY; FEMALE; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; NEOPLASM STAGING; THYROID NEOPLASMS; TUMOR MICROENVIRONMENT; YOUNG ADULT;

EID: 84890376038     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0560     Document Type: Article

References (57)

1. Trinchieri G 1989 Biology of natural killer cells. Adv Immunol 47: 187-376. (Pubitemid 20010960)
2. Cooper MA, Fehniger TA, Caligiuri MA 2001 The biology of human natural killer-cell subsets. Trends Immunol 22: 633-640. (Pubitemid 33043908)
3. Vivier E, Raulet DH, Moretta A, Caliqiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Uqolini S 2011 Innate or adaptive immunity? The example of natural killer cells. Science 331: 44-49.
4. Caligiuri M 2008 Human natural killer cells. Blood 112: 461-469.
5. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA 2001 Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood 31: 3121-3127.
6. Baume DM, Robertson MJ, Levine H, Manley TJ, Schow PW, Ritz J 1992 Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells. Eur J Immunol 22: 1-6.
7. Moller MJ, Kammerer R, von Kleist S 1998A distinct distribution of natural killer cell subgroups in human tissues and blood. Int J Cancer 78: 533-538. (Pubitemid 28507173)
8. Drake PM, Gunn MD, Charo IF, Tsou CL, Zhou Y, Huang L, Fisher SJ 2001 Human placental cytotrophoblasts attract monocytes and CD56(bright) natural killer cells via the actions of monocyte inflammatory protein 1alpha. J Exp Med 193: 1199-1212. (Pubitemid 32488372)
9. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, Caligiuri MA 2003 CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: as potential new link between adaptive and innate immunity. Blood 101: 3052-3057. (Pubitemid 36857995)
10. Perussia B, Chen Y, Loza MJ 2005 Peripheral NK cell phenotypes: multiple changing of faces of an adapting, developing cell. Mol Immunol 42: 385-395. (Pubitemid 39655944)
11. Freud AG, Caligiuri MA 2006 Human natural killer cell development. Immunol Rev 214: 56-72. (Pubitemid 44707902)
12. Konjevic G, Schlesinger B, Cheng L, Olsen KJ, Podack ER, Spuzic I 1995 Analysis of perforin expression in human peripheral blood lymphocytes, CD56+natural killer cell subsets and its induction by interleukin-2. Immunol Invest 24: 499-507.
13. Fauriat C, Long EO, Ljunggren HG, Bryceson YT 2010 Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 115: 2167-2176.
14. De Maria A, Bozzano F, Cantoni C, Moretta L 2011 Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+NK cells as rapid produces of abundant IFN-gamma on activation. Proc Natl Acad Sci USA 108: 728-732.
15. Karre K, Lujunggren HG, Piontek G, Kiessling R 1986 Selective rejection of H-2 deficient lymphoma variants suggests alternative immune defence strategy. Nature 319: 675-678. (Pubitemid 16119452)
16. Lanier LL 2008 Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9: 495-502. (Pubitemid 351560518)
17. Moretta L, Moretta A 2004 Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 23: 255-259. (Pubitemid 38294490)
18. Biassoni R 2008 Natural killer cell receptors. Adv Exp Med Biol 640: 35-52.
19. Gasser S, Raoulet DH 2006 Activation and self-tolerance of natural killer cells. Immunol Rev Dec 214: 130-142. (Pubitemid 44707907)
20. Sentman CL, Barber MA, Barber A, Zhang T 2006 NK cell receptors as tools in cancer immunotherapy. Adv Cancer Res 95: 249-292. (Pubitemid 44066528)
21. Robertson MJ, Soiffer RJ, Wolf SF, Manley TJ, Donahue C,Young D, Herrmann SH, Ritz J 1992 Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med 175:779.
22. Fehniger TA, Caligiuri MA 2001 Interleukin 15: biology and relevance to human disease. Blood 97: 14-32. (Pubitemid 32061238)
23. Kasaian MT, Whitters MJ, Carter LL, Lowe LD, Jussif JM, Deng B, Johnson KA, Witek JS, Senices M, Konz RF, Wurster AL, Donaldson DD, Collins M, Young DA, Grusby MJ 2002 IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16: 559-569. (Pubitemid 34442580)
24. Ferlazzo G, Thomas D, Lin SL, Goodman K, Morandi B, Muller WA, Moretta A. Munz C 2004 The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 172: 1455-1462. (Pubitemid 38116788)
25. Loza MJ, Perussia B 2004 The IL-12 signature: NK cell terminal CD56+ high stage and effector functions. J Immunol 172: 88-96. (Pubitemid 38020459)
26. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K 2000 Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356: 1795-1799.
27. Albertsson PA, Basse PH, Hokland M, Goldfarb RH, Nagelkerke 326 JF, Nannmark U, Kuppen PJ 2003 NK cells and the tumor microenviroment: implications for NK-cell function and anti-tumor activity. Trends Immunol 24: 603-609. (Pubitemid 37338529)
28. Mazzaferri EL, Young RL 1981 Papillary thyroid carcinoma: a ten year follow up report of the impact of therapy in 576 patients. Am J Med 70: 511-518. (Pubitemid 11153883)
29. Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G, Ratto GB, Mingari MC, Moretta L, Ferlazzo G 2008 Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16 (-) cells and display an impaired capability to kill tumor cells. Cancer 112: 863-875. (Pubitemid 351240580)
30. Takanami I, Takeuchi K, Giga M 2001 The prognostic value of natural 348 killer cell infiltration in resected pulmonary adenocarcinoma. J Thorac Cardiovasc Surg 121: 1058-1063.
31. Belisle JA, Gubbels JA, Raphael CA, Migneault M, Rancourt C, Connor JP, Patankar MS 2007 Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology 122: 418-429. (Pubitemid 47556479)
32. Murta EF, de Andrade JM, Falcao RP, Bighetti S 2000 Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy. Tumori 86: 403-407.
33. Modi J, Patel A, Terrell R, Tuttle RM, Francis GL 2003 Papillary thyroid carcinoma from young adults and children contain a mixture of lymphocytes. J Clin Endocrinol Metab 88: 4418-4425. (Pubitemid 37153752)
34. Gogali F, Paterakis G, Rassidakis GZ, Kaltsas G, Liakou CI, Gousis P, Neonakis E, Manoussakis MN, Liapi C 2012 Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK cells in the papillary carcinoma of thyroid. J Clin Endocrinol Metab 97:1474- 1482.
35. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L 2012 Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 12: 239-252.
36. Gulubova M, Manolova I, Kyurkchiev D, Julianov A, Altunkova I 2009 Decrease in intrahepatic CD56+ lymphocytes in gastric and colorectal cancer patients with liver metastases. APMIS 117: 870-879.
37. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, Aridome K, Hokita S, Aikou T 2000 Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 88: 577-583. (Pubitemid 30056932)
38. Jusufovic E, Iljazovic E, Kosnik M, Keser D, Korosec P, Zukic E, Prnjavorac B, Sejdinovic R, Ajanovic E 2011 Local CD4+, CD8+ and CD56+ reactions to lung cancer in regard to pathohistological type and clinical stage. Med Glas Ljek komore Zenicko-doboj kantona 8: 101-108.
39. Lanier LL 2001 On guard-activating NK cell receptors. Nat Immunol 2: 23-27.
40. Konjević G, Mirjacić Martinović K, Jurisić V, Babović N, Spuzić I 2009 Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: decreased NKG2D and increased CD158a receptors on CD3-CD16+NK cells Biomarkers 14: 258-270.
41. Iwatani Y, Hidaka Y, Matsuzuka F, Kuma K, Amino N 1993 Intrathyroidal lymphocyte subsets, including unusual CD4+CD8+cells and CD3loTCR alpha beta lo/-CD4-CD8- cells, in autoimmune thyroid disease. Clin Exp Immunol 93: 430-436. (Pubitemid 23276271)
42. Solerte SB, Precerutti S, Gazzaruso C, Locatelli E, Zamboni M, Schifino N, Bonacasa R, Rondanelli M, Taccani D, Ferrari E, Fioravanti M 2005 Defect of a subpopulation of natural killer immune cells in Graves' disease and Hashimoto's thyroiditis: normalizing effect of dehydroepiandrosterone sulfate. Eur J Endocrinol 152: 703-712. (Pubitemid 40744538)
43. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH 1986 The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 136: 4480-4486. (Pubitemid 16090665)
44. Chan A, Hong DL, Atzberger A, Kollnberger S, Filer AD, Buckley CD, McMichael A, Enver T, Bowness P 2007 CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol 179: 89-94. (Pubitemid 46986521)
45. Quyang Q, Baerlocher G, Vulto I, Lansdorp PM 2007 Telomere length in human natural killer cell subsets. Ann N Y Acad Sci 1106: 240-252. (Pubitemid 47443037)
46. Freud AG, Yokohama A, Becknell B, Lee MT, Mao HC, Ferketich AK, Caligiuri MA 2006 Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 203: 1033-1043.
47. Mamessier E, Sylvain A, Bertucci F, Castellano R, Finetti P, Houvenaeghel G, Charaffe-Jaufret E, Birnbaum D, Moretta A, Olive D 2011 Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAMmediated NK cell recognition. Cancer Res Nov 71: 6621-6632.
48. National Cancer Institute 2011 SEER cancer statistics review 1975-2008. Available at http://seer.cancer.gov/csr/1975- 2008 (accessed November 2010).
49. Mazzaferri EL, Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97: 418-428. (Pubitemid 24345593)
50. Schlumberger M, Sherman SI 2009 Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances. Thyroid 19:1393- 1400.
51. Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, Caillou B, Travagli JP, Parmentier C 1985 Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 55: 794-804. (Pubitemid 15173518)
52. Rouxel A, Hejblum G, Bernier MO, Boëlle PY, Ménégaux F, Mansour G, Hoang C, Aurengo A, Leenhardt L 2004 Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. J Clin Endocrinol Metab 89: 5362-5368. (Pubitemid 39518409)
53. Ortiz S, Rodríguez JM, Parrilla P, Pérez D, Moreno-Gallego A, Rios A, Soria T 2001 Recurrent papillary thyroid cancer: analysis of prognostic factors including the histological variant. Eur J Surg 167: 406-412. (Pubitemid 32607814)
54. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, Vathaire FD, Schlumberger M 2006 Long term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91: 2892-2899. (Pubitemid 44271732)
55. Casara D, Rubello D, Saladini G, Masarotto G, Favero A, Girelli ME, Busnardo B 1993 Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 34: 1626-1631. (Pubitemid 23295368)
56. Schlumberger MJ 1998 Papillary and follicular thyroid carcinoma. N Engl J Med 29: 297-306. (Pubitemid 28065257)
57. Kapiteijn E, Schneider TC, Morreau H, Gelderblon H, Nortier JWR, Smit JWA 2012 New treatment modalities in advanced thyroid cancer. Annals of Oncology 23: 10-18.